What question did this study set out to answer?

February 13, 2026Cochrane library1 citations

Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer

YGYa GaoShandong University MLMing LiuNanyang Technological University LLLei LiBGI Group (China)

Key Points

The study aims to evaluate the effectiveness of combining PD-1 or PD-L1 inhibitors with chemotherapy in early triple-negative breast cancer treatment.
Analyzed treatment outcomes of PD-1/PD-L1 inhibitors combined with chemotherapy before surgery versus chemotherapy alone.
Compared effects of the same combination after surgery.
Evaluated pathological response, event-free survival (EFS), and overall survival (OS).
Combining PD-1/PD-L1 inhibitors with chemotherapy before surgery improves pathological response and EFS/OS.
Post-surgery, the combination shows little to no improvement in EFS and OS compared to chemotherapy alone.
The addition of PD-1 or PD-L1 inhibitors likely increases immune-related serious adverse events (SAEs).

Abstract

Combining PD-1 or PD-L1 inhibitors with chemotherapy compared to chemotherapy alone before breast cancer surgery improves pathological response, EFS, and OS in early TNBC. In contrast, the combination of PD-1/PD-L1 inhibitors with chemotherapy after breast cancer surgery may have little to no effect on EFS and OS in early-stage TNBC when compared with chemotherapy alone. The addition of PD-1 or PD-L1 inhibitors probably increases immune-related SAEs.

AIに質問

Bookmark

View Full Paper